These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 20357056

  • 21. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.
    Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM.
    J Clin Microbiol; 2005 Jun; 43(6):2856-65. PubMed ID: 15956409
    [Abstract] [Full Text] [Related]

  • 22. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N, Guiso N.
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [Abstract] [Full Text] [Related]

  • 23. [Application of DNA microcarriers for evaluation of mice splenocytes genes expression after immunization with pertussis vaccines and challenged with different B. pertussis strains].
    Gzyl A, Woyciechowska-Oczko M, Jarzab B, Augustynowicz E, Mosiej E, Slusarczyk J.
    Med Dosw Mikrobiol; 2007 Sep; 59(2):149-59. PubMed ID: 17929412
    [Abstract] [Full Text] [Related]

  • 24. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.
    Martin SW, Pawloski L, Williams M, Weening K, DeBolt C, Qin X, Reynolds L, Kenyon C, Giambrone G, Kudish K, Miller L, Selvage D, Lee A, Skoff TH, Kamiya H, Cassiday PK, Tondella ML, Clark TA.
    Clin Infect Dis; 2015 Jan 15; 60(2):223-7. PubMed ID: 25301209
    [Abstract] [Full Text] [Related]

  • 25. [Analysis of chosen parameters of immuno response in mice immunized with whole-cell or acellular pertussis vaccines and challenged with B. pertussis strains harbouring different ptxS1/prn allele genes combinations].
    Gzyl A, Augustynowicz E, Zawadka M, Rabczenko D, Slusarczyk J.
    Med Dosw Mikrobiol; 2007 Jan 15; 59(2):137-47. PubMed ID: 17929411
    [Abstract] [Full Text] [Related]

  • 26. [Immunogenicity and safety of vaccine preparations based on circulating Bordetella pertussis strains].
    Zaĭtsev EM, Mertsalova NIu, Britsina MV, Ozeretskovskaia MN, Bazhanova IG, Shinkarev AS, Poddubikov AV.
    Zh Mikrobiol Epidemiol Immunobiol; 2014 Jan 15; (4):18-22. PubMed ID: 25286523
    [Abstract] [Full Text] [Related]

  • 27. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
    Huh DH, Han SB, Shin HJ, Ahn DH, Choi GS, Kang KR, Kim BR, Kang JH.
    J Microbiol Immunol Infect; 2018 Dec 15; 51(6):732-739. PubMed ID: 28720318
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange.
    Buasri W, Impoolsup A, Boonchird C, Luengchaichawange A, Prompiboon P, Petre J, Panbangred W.
    BMC Microbiol; 2012 Apr 23; 12():61. PubMed ID: 22524455
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Increase in pertussis cases along with high prevalence of two emerging genotypes of Bordetella pertussis in Perú, 2012.
    Bailon H, León-Janampa N, Padilla C, Hozbor D.
    BMC Infect Dis; 2016 Aug 17; 16():422. PubMed ID: 27530444
    [Abstract] [Full Text] [Related]

  • 33. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine.
    Boursaux-Eude C, Thiberge S, Carletti G, Guiso N.
    Vaccine; 1999 Jun 04; 17(20-21):2651-60. PubMed ID: 10418915
    [Abstract] [Full Text] [Related]

  • 34. Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles.
    Ormazábal M, Bartel E, Gaillard ME, Bottero D, Errea A, Zurita ME, Moreno G, Rumbo M, Castuma C, Flores D, Martín MJ, Hozbor D.
    Vaccine; 2014 Oct 21; 32(46):6084-90. PubMed ID: 25240753
    [Abstract] [Full Text] [Related]

  • 35. Molecular epidemiology of Bordetella pertussis and analysis of vaccine antigen genes from clinical isolates from Shenzhen, China.
    Wu S, Hu Q, Yang C, Zhou H, Chen H, Zhang Y, Jiang M, He Y, Shi X.
    Ann Clin Microbiol Antimicrob; 2021 Aug 18; 20(1):53. PubMed ID: 34407803
    [Abstract] [Full Text] [Related]

  • 36. Comparison of recombinant and native pertactin of Bordetella pertussis.
    Xu Y, Zhang S, Bolgiano B, Tan Y, Asokanathan C, Zhang H, Xing D, Wang J.
    Vaccine; 2011 Feb 24; 29(10):1974-80. PubMed ID: 21216309
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pertactin-deficient Bordetella pertussis isolates in Poland-a country with whole-cell pertussis primary vaccination.
    Polak M, Zasada AA, Mosiej E, Krysztopa-Grzybowska K, Witkowski L, Rzeczkowska M, Piekarska K, Lutyńska A.
    Microbes Infect; 2019 Feb 24; 21(3-4):170-175. PubMed ID: 30580013
    [Abstract] [Full Text] [Related]

  • 39. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.
    Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC.
    Infect Immun; 2001 Sep 24; 69(9):5520-8. PubMed ID: 11500425
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.